INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 48 filers reported holding INOZYME PHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $5,602,000 | -56.4% | 2,090,436 | -22.5% | 0.11% | -57.7% |
| Q2 2022 | $12,862,000 | +34.1% | 2,696,372 | +15.0% | 0.26% | +23.8% |
| Q1 2022 | $9,590,000 | -40.0% | 2,344,786 | 0.0% | 0.21% | -36.1% |
| Q4 2021 | $15,991,000 | -41.2% | 2,344,786 | 0.0% | 0.34% | -36.8% |
| Q3 2021 | $27,176,000 | -26.8% | 2,344,786 | +7.6% | 0.53% | -19.7% |
| Q2 2021 | $37,130,000 | -4.5% | 2,178,985 | +10.9% | 0.66% | -19.2% |
| Q1 2021 | $38,887,000 | +63.8% | 1,964,000 | +70.7% | 0.82% | +74.2% |
| Q4 2020 | $23,742,000 | -21.5% | 1,150,299 | 0.0% | 0.47% | -36.3% |
| Q3 2020 | $30,241,000 | – | 1,150,299 | – | 0.74% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 4,494,851 | $18,878,374 | 7.53% |
| CHI Advisors LLC | 1,270,027 | $5,334,112 | 2.11% |
| Samsara BioCapital, LLC | 1,562,500 | $6,562,500 | 2.01% |
| Affinity Asset Advisors, LLC | 1,379,852 | $5,795,378 | 1.63% |
| Sofinnova Investments, Inc. | 4,280,308 | $17,977,294 | 1.13% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,234,907 | $5,186,609 | 0.94% |
| Octagon Capital Advisors LP | 1,300,000 | $5,460,000 | 0.84% |
| NEA Management Company, LLC | 2,437,689 | $10,238,294 | 0.79% |
| Knott David M Jr | 454,008 | $1,907 | 0.73% |
| Rock Springs Capital Management LP | 3,681,174 | $15,460,931 | 0.41% |